IGM Biosciences Overview
- Year Founded
-
1993
- Status
-
Acquired/Merged
- Employees
-
16
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$78M
IGM Biosciences General Information
Description
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Contact Information
Website
www.igmbio.com(Operating Subsidiary)
Corporate Office
- 325 East Middlefield Road
- Mountain View, CA 94043
- United States
Corporate Office
- 325 East Middlefield Road
- Mountain View, CA 94043
- United States
IGM Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 14-Aug-2025 | $78M | Completed | Generating Revenue | ||
| 6. PIPE | 22-Jun-2023 | Completed | Generating Revenue | |||
| 5. IPO | 18-Sep-2019 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 08-Jul-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B1) | 23-Mar-2012 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series B) | 16-Jul-2010 | $1.3M | $2.8M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 25-Aug-1993 | $1.5M | $1.5M | Completed | Product Development |
IGM Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 3,060,000 | $0.010000 | $0.04 | $0.5 | $0.5 | 1x | $0.5 | 10.71% |
IGM Biosciences Comparisons
Industry
Financing
Details
IGM Biosciences Competitors (57)
One of IGM Biosciences’s 57 competitors is Compass Therapeutics, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Mustang Bio | Formerly VC-backed | Waltham, MA | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA |
IGM Biosciences Patents
IGM Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026072101-A1 | Method for purifying biomixtures | Pending | 27-Sep-2024 | ||
| WO-2025117221-A1 | Multimeric anti-respiratory syncytial virus binding molecule | Inactive | 27-Nov-2023 | ||
| WO-2024229151-A2 | Multimeric coronavirus binding molecules and uses thereof | Inactive | 02-May-2023 | ||
| WO-2024229151-A3 | Multimeric coronavirus binding molecules and uses thereof | Inactive | 02-May-2023 | ||
| US-20260347469-A1 | T cell costimulatory multimeric binding molecules and uses thereof | Pending | 06-Jan-2023 | C07K16/2809 |
IGM Biosciences Signals
IGM Biosciences Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Baker Brothers Investments | Hedge Fund | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Redmile Group | Venture Capital | Minority | ||
| Topsoe | PE-Backed Company | Minority | ||
| Vivo Capital | Venture Capital | Minority |
IGM Biosciences ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
41.15 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
IGM Biosciences FAQs
-
When was IGM Biosciences founded?
IGM Biosciences was founded in 1993.
-
Where is IGM Biosciences headquartered?
IGM Biosciences is headquartered in Mountain View, CA.
-
What is the size of IGM Biosciences?
IGM Biosciences has 16 total employees.
-
What industry is IGM Biosciences in?
IGM Biosciences’s primary industry is Drug Discovery.
-
Is IGM Biosciences a private or public company?
IGM Biosciences is a Private company.
-
What is the current valuation of IGM Biosciences?
The current valuation of IGM Biosciences is .
-
What is IGM Biosciences’s current revenue?
The current revenue for IGM Biosciences is .
-
How much funding has IGM Biosciences raised over time?
IGM Biosciences has raised $317M.
-
Who are IGM Biosciences’s investors?
Baker Brothers Investments, Janus Henderson Investors, Redmile Group, Topsoe, and Vivo Capital have invested in IGM Biosciences.
-
Who are IGM Biosciences’s competitors?
Compass Therapeutics, Kite Pharma, Mustang Bio, Instil Bio, and Allogene Therapeutics are some of the 57 competitors of IGM Biosciences.
-
When was IGM Biosciences acquired?
IGM Biosciences was acquired on 14-Aug-2025.
-
Who acquired IGM Biosciences?
IGM Biosciences was acquired by Concentra Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process